Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.62 |
| ▸ | CTSD | P07339 | 1/20 | 0.62 |
| ▸ | DHFR | P00374 | 1/20 | 0.58 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.50 |
| ▸ | PTPRC | P08575 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767713 | 0.77 | BACE1 (1.00) | BACE1CTSDNCF1ACHE | |
| SCHEMBL9932 | 0.76 | BACE1 (0.59) | BACE1CTSDACHE | |
| SCHEMBL21223574 | 0.74 | DHFR (0.49) | DHFRTLR8PTPRCNCF1PDE3A | |
| SCHEMBL3793772 | 0.73 | PTPRC (0.55) | DHFRPTPRCPIP4K2APDE3A | |
| SCHEMBL3793105 | 0.72 | PTPRC (0.55) | DHFRPTPRCNR3C1 | |
| SCHEMBL22926832 | 0.71 | BACE1 (1.00) | BACE1CTSDDHFRNCF1 | |
| SCHEMBL15639344 | 0.70 | BACE1 (0.67) | BACE1CTSD | |
| SCHEMBL14823126 | 0.70 | S1PR1 (0.54) | DHFRPTPRCNR3C1ABL1PIP4K2A | |
| SCHEMBL13888550 | 0.70 | DHFR (0.74) | DHFRPTPRCABL1PIP4K2APDE10A | |
| SCHEMBL9711 | 0.69 | BACE1 (0.61) | BACE1CTSDNCF1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2504315-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011063233-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | BACE1 1/4885CTSD 827/4885DHFR 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.